Ipamorelin

Ipamorelin is a highly selective growth hormone secretagogue pentapeptide that stimulates GH release from anterior pituitary somatotroph cells without significantly affecting cortisol, prolactin, FSH, LH, or TSH levels. This remarkable selectivity distinguishes it from other GHRPs and makes it one of the cleanest GH-releasing peptides studied in preclinical and clinical settings. Ipamorelin acts through the ghrelin receptor (GHS-R1a) but with a unique binding profile that produces GH release comparable to GHRP-6 while minimizing the appetite-stimulating and cortisol-elevating side effects. Research applications span investigations into GH axis modulation, bone mineral density and bone metabolism studies, body composition analysis, and gastrointestinal motility research. Notably, Ipamorelin has been studied for its prokinetic effects on gastric and colonic motility, suggesting potential applications in post-operative ileus research. Its favorable safety profile in clinical studies has made it a preferred compound for translational research bridging preclinical and clinical GH axis investigation.